Although several studies have suggested FGF2 as a therapeutic target in diseases such as rheumatoid arthritis and other bone diseases,40 and a number of anti-FGF2 monoclonal antibodies (mAbs) have been developed previously to neutralize various activities of FGF2 in vitro and, in some cases, in vivo,41, 42, 43 FGF2 has not been developed for retinal angiogenic eye disease. This evidence concerns the gene FGF2 and eye disorder.